CA2922251C - Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics - Google Patents

Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics Download PDF

Info

Publication number
CA2922251C
CA2922251C CA2922251A CA2922251A CA2922251C CA 2922251 C CA2922251 C CA 2922251C CA 2922251 A CA2922251 A CA 2922251A CA 2922251 A CA2922251 A CA 2922251A CA 2922251 C CA2922251 C CA 2922251C
Authority
CA
Canada
Prior art keywords
csf
functional fragment
seq
treatment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922251A
Other languages
English (en)
French (fr)
Other versions
CA2922251A1 (en
Inventor
Thomas DR. WAGNER
Malin CARLSSON
Margit STAUM KALTOFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2922251A1 publication Critical patent/CA2922251A1/en
Application granted granted Critical
Publication of CA2922251C publication Critical patent/CA2922251C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2922251A 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics Active CA2922251C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361871904P 2013-08-30 2013-08-30
US201361871900P 2013-08-30 2013-08-30
US61/871,900 2013-08-30
US61/871,904 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Publications (2)

Publication Number Publication Date
CA2922251A1 CA2922251A1 (en) 2015-03-05
CA2922251C true CA2922251C (en) 2023-10-17

Family

ID=51454704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922251A Active CA2922251C (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Country Status (12)

Country Link
US (2) US10745475B2 (enExample)
EP (2) EP3889178A1 (enExample)
JP (4) JP2016536327A (enExample)
KR (3) KR20240090993A (enExample)
CN (2) CN118178647A (enExample)
AU (3) AU2014314053C1 (enExample)
BR (1) BR112016003293A8 (enExample)
CA (1) CA2922251C (enExample)
ES (1) ES2860480T3 (enExample)
MX (2) MX385854B (enExample)
RU (1) RU2714919C2 (enExample)
WO (1) WO2015028657A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
PL3328887T3 (pl) * 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
SG11202008934PA (en) * 2018-03-14 2020-10-29 Univ Indiana Res & Tech Corp Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
AU2001232267A1 (en) 2000-02-14 2001-08-20 Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases Remedies for hepatitis c
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
EP1576011B1 (en) 2002-10-30 2009-08-12 Genentech, Inc. Inhibition of il-17 production
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005316405A1 (en) 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ME02191B (me) 2005-04-18 2016-02-20 Amgen Res Munich Gmbh Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
RS55526B1 (sr) 2006-02-08 2017-05-31 Morphotek Inc Antigenski gm-csf peptidi i antitela gm-csf
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
CN102037016B (zh) 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 针对粒细胞巨噬细胞集落刺激因子的抗体
AU2009242088B2 (en) 2008-04-29 2014-08-21 Amgen Research (Munich) Gmbh Inhibitors of GM-CSF and IL-17 for therapy
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
EP2427495A1 (en) 2009-05-05 2012-03-14 MorphoSys AG Treatment for multiple sclerosis
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CN102686241A (zh) 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
EP3916013A1 (en) 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN109562493B (zh) 2016-08-03 2021-10-26 古河电气工业株式会社 含金属粒子的组合物

Also Published As

Publication number Publication date
AU2020203917A1 (en) 2020-07-02
BR112016003293A2 (pt) 2017-11-21
RU2016109944A3 (enExample) 2018-07-09
EP3039039A1 (en) 2016-07-06
CN118178647A (zh) 2024-06-14
WO2015028657A1 (en) 2015-03-05
JP2024123249A (ja) 2024-09-10
AU2014314053C1 (en) 2023-11-02
KR20220045064A (ko) 2022-04-12
JP2022105160A (ja) 2022-07-12
US10745475B2 (en) 2020-08-18
CN105705518A (zh) 2016-06-22
MX2021010472A (es) 2021-10-01
US20210171620A1 (en) 2021-06-10
MX385854B (es) 2025-03-18
RU2016109944A (ru) 2017-10-06
KR20240090993A (ko) 2024-06-21
EP3039039B1 (en) 2021-03-10
EP3889178A1 (en) 2021-10-06
KR20160044035A (ko) 2016-04-22
ES2860480T3 (es) 2021-10-05
CA2922251A1 (en) 2015-03-05
AU2014314053B2 (en) 2020-03-12
MX2016002177A (es) 2016-06-28
US11795216B2 (en) 2023-10-24
US20160355584A1 (en) 2016-12-08
RU2714919C2 (ru) 2020-02-21
JP2020109108A (ja) 2020-07-16
BR112016003293A8 (pt) 2022-08-16
AU2014314053A1 (en) 2016-02-11
AU2023210647A1 (en) 2023-10-12
JP2016536327A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
AU2011325134B2 (en) Methods of treating rheumatoid arthritis using IL-17 antagonists
ES2994774T3 (en) Methods for preventing or treating allergy by administering an il-4r antagonist
JP2020073470A (ja) 抗ｉｌ２３抗体を使用してクローン病を治療するための方法
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
AU2015313827C1 (en) Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
KR20230155586A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
JP2025000638A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
CN112312971A (zh) 结合cd123和cd3的双特异性抗体的给药
CN112512578A (zh) 结合cd123和cd3的双特异性抗体的给药
CN111344043A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP2023536653A (ja) Ｇｐ１３０結合分子および使用方法
EP4006053A1 (en) Method for treating autoimmune disease by il-17 antagonist
AU2014259526B2 (en) Methods of treating ankylosing spondylitis using IL-17 antagonists
Crowley Bimekizumab. Humanized monoclonal antibody demonstrating dual inhibition of IL-17A and IL-17F, Treatment of psoriasis and psoriatic arthritis
WO2015028666A1 (en) Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
EP2341937B1 (en) Composition for treating disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190827

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260413